News | Neuro Imaging | July 05, 2019

Delta T1 Maps Provide Quantitative, Automated Solution to Assess Brain Tumor Burden

Clinical data shows Delta T1 maps from Imaging Biometrics on par with central reader analysis but offer substantial time and cost savings

Delta T1 Maps Provide Quantitative, Automated Solution to Assess Brain Tumor Burden

July 5, 2019 — Imaging Biometrics LLC (IB) a subsidiary of IQ-AI Ltd., is highlighting a recently published study in the American Journal of Neuroradiology1 confirming the value of IB’s dT1 maps in streamlining routine radiology workflows and multi-center clinical trials.

The study confirms the value of IB’s dT1 maps in streamlining routine radiology workflows and multi-center clinical trials.

Objective, accurate and reproducible methods to measure brain tumor volumes are important in the assessment of treatment response. Contrast-enhanced magnetic resonance imaging (MRI) is the most common approach to monitor treatment, but it is highly variable and confounded by numerous factors including differences in vendor platforms, field strengths and general MRI system instabilities. It is well-acknowledged that these factors contribute to the large disagreement of up to 50-60 percent between neuroradiologists when assessing tumor burden and evaluating treatment response.

Quantitative dT1 maps offer an elegant and automated solution that overcome these challenges and, therefore, have the potential to cause a disruptive shift in how brain tumor burden is assessed. dT1 maps compare calibrated pre- (T1) and post-contrast (T1+C) anatomic images. The calibration process, exclusive to IB, translates the relative and variable MR intensity values to a fixed and consistent scale. This built-in step is independent of scanner platform, field strength and time point, and has been shown superior over manual tissue normalization algorithms.

The secondary analysis of multicenter clinical trial data was performed by lead author Kathleen Schmainda, Ph.D., from the Medical College of Wisconsin, and colleagues. In total, 123 patients from 23 institutions enrolled in the study. The study compared IB’s dT1 maps to two primary readers and one adjudicator to manually delineate enhancing lesions. The results proved the dT1 method to be comparable to expert reads for determining early tumor progression and proved superior for further distinguishing treatment responders from non-responders at the week 8 time point. Another key outcome of the study was that only the dT1 method could predict differences in outcomes at the week 8 time point.\

For more information: www.imagingbiometrics.com

 

Reference

1. Schmainda K.M., Prah M.A., Zhang Z., et al. Quantitative Delta T1 (dT1) as a Replacement for Adjudicated Central Reader Analysis of Contrast-Enhancing Tumor Burden: A Subanalysis of the American College of Radiology Imaging Network 6677/Radiation Therapy Oncology Group 0625 Multicenter Brain Tumor Trial. American Journal of Neuroradiology, June 27, 2019. doi: 10.3174/ajnr.A6110

Related Content

An example of the MRI scans showing long-term and short-term survival indications. #MRI

An example of the MRI scans showing long-term and short-term survival indications. Image courtesy of Case Western Reserve University

News | Magnetic Resonance Imaging (MRI) | February 21, 2020
February 21, 2020 — ...
A cutting-edge magnet resonance imaging (MRI) technique to detect iron deposits in different brain regions can track declines in thinking, memory and movement in people with Parkinson's disease #Parkinsons #MRI

Summary steps of the processing pipeline for QSM reconstruction (phase pre-processing and map estimation) and whole brain/regional analysis. ANTs, advanced normalisation tools; MP-RAGE, magnetisation-prepared, 3D, rapid, gradient-echo; MSDI, multi-scale dipole inversion; QSM, quantitative susceptibility mapping; ROI, region of interest; SWI, susceptibility weighted imaging.

News | Magnetic Resonance Imaging (MRI) | February 21, 2020
February 21, 2020 — A cutting-edge...
Two magnetic resonance imaging (MRI) findings — joint capsule edema and thickness at the axillary recess, specifically — proved useful in predicting stiff shoulder in patients with rotator cuff tears, according to an ahead-of-print article in the May issue of the American Journal of Roentgenology (AJR)

A: Oblique coronal fat-suppressed T2-weighted MR image shows normal hypointense joint capsule at axillary recess (arrow). Note full-thickness tear of supraspinatus tendon (arrowheads) B: Oblique sagittal proton density MR image shows preserved subcoracoid fat triangle (asterisk). Image courtesy of the American Journal of Roentgenology (AJR)

News | Magnetic Resonance Imaging (MRI) | February 20, 2020
February 20, 2020 — Two ma...
Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure

Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure. This picture shows a circle of hydrogel that was irradiated on the left half, which is slightly pink; whereas the right half of the gel is not irradiated and remains colorless.

News | Radiation Therapy | February 18, 2020
February 18, 2020 — More than half of all cancer patients undergo radiation therapy and the dose is critical.
Hyperfine Research, Inc. announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the world’s first bedside Magnetic Resonance Imaging (MRI) system

Hyperfine's point-of-care MRI wheels directly to the patient’s bedside, plugs into a standard electrical wall outlet, and is controlled via a wireless tablet. Photo courtesy of Business Wire

News | Magnetic Resonance Imaging (MRI) | February 12, 2020
February 12, 2020 — Hyperfine Research, Inc. announced that i
The magnetic resonance imaging (MRI) contrast agents market is expected to grow rapidly

Image courtesy of GE Healthcare

News | Magnetic Resonance Imaging (MRI) | February 11, 2020
February 11, 2020 — The magnetic resonance imaging (MRI) contrast agents market is expected to grow rapidly in the fo
Accuray TomoTherapy total body irradiation
News | Radiation Therapy | February 07, 2020
February 7, 2020 — Accuray Incorporated announced that two new studies demonstrate the benefits of the ...
Gadolinium-based contrast agents

UT Dallas faculty members who collaborated with Dr. Jeremiah Gassensmith (center, back), associate professor of chemistry and biochemistry, include Dr. Lloyd Lumata (left, back), assistant professor of physics, and Dr. Steven Nielsen, associate professor of chemistry. Chemistry graduate students in Gassensmith’s lab include (from left, front) Oliva Brohlin, Arezoo Shahrivarkevishahi and Laurel Hagge.

News | Contrast Media | February 06, 2020
February 6, 2020 — University of Texas at Dallas researchers
Qynapse, a medical technology company, announced that it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its QyScore software
News | Information Technology | February 04, 2020
February 4, 2020 — Qynapse, a medical technology company, anno